JP2021514625A - 抗muc1抗体およびil−15を含む融合タンパク質構築物 - Google Patents
抗muc1抗体およびil−15を含む融合タンパク質構築物 Download PDFInfo
- Publication number
- JP2021514625A JP2021514625A JP2020544404A JP2020544404A JP2021514625A JP 2021514625 A JP2021514625 A JP 2021514625A JP 2020544404 A JP2020544404 A JP 2020544404A JP 2020544404 A JP2020544404 A JP 2020544404A JP 2021514625 A JP2021514625 A JP 2021514625A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cells
- fusion protein
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 247
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 247
- 102000003812 Interleukin-15 Human genes 0.000 title claims abstract description 228
- 108090000172 Interleukin-15 Proteins 0.000 title claims abstract description 228
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 107
- 102100034256 Mucin-1 Human genes 0.000 claims abstract description 73
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims abstract description 67
- 201000011510 cancer Diseases 0.000 claims abstract description 52
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 49
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 43
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 219
- 230000027455 binding Effects 0.000 claims description 148
- 239000012634 fragment Substances 0.000 claims description 109
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 108
- 238000011282 treatment Methods 0.000 claims description 64
- 230000014509 gene expression Effects 0.000 claims description 60
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 47
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 47
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 36
- 102000056003 human IL15 Human genes 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 102000005962 receptors Human genes 0.000 claims description 20
- 108020003175 receptors Proteins 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 20
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 18
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 17
- 230000004988 N-glycosylation Effects 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 10
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 10
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 10
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 10
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 101150013553 CD40 gene Proteins 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 238000004393 prognosis Methods 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 206010017533 Fungal infection Diseases 0.000 claims description 5
- 206010061598 Immunodeficiency Diseases 0.000 claims description 5
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 5
- 208000031888 Mycoses Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000030852 Parasitic disease Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 230000007813 immunodeficiency Effects 0.000 claims description 5
- 102000002467 interleukin receptors Human genes 0.000 claims description 5
- 108010093036 interleukin receptors Proteins 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims description 4
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 230000005965 immune activity Effects 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 107
- 239000000427 antigen Substances 0.000 abstract description 80
- 108091007433 antigens Proteins 0.000 abstract description 80
- 102000036639 antigens Human genes 0.000 abstract description 80
- 210000000822 natural killer cell Anatomy 0.000 abstract description 67
- 210000004027 cell Anatomy 0.000 description 244
- 102000004127 Cytokines Human genes 0.000 description 90
- 108090000695 Cytokines Proteins 0.000 description 90
- 125000005647 linker group Chemical group 0.000 description 65
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 58
- 210000004881 tumor cell Anatomy 0.000 description 58
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 56
- 210000002865 immune cell Anatomy 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 44
- 229940024606 amino acid Drugs 0.000 description 42
- 150000001413 amino acids Chemical class 0.000 description 42
- 102000004196 processed proteins & peptides Human genes 0.000 description 42
- 230000013595 glycosylation Effects 0.000 description 41
- 238000006206 glycosylation reaction Methods 0.000 description 41
- 229940126618 pankomab Drugs 0.000 description 41
- 229920001184 polypeptide Polymers 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 37
- 230000000694 effects Effects 0.000 description 36
- 230000003013 cytotoxicity Effects 0.000 description 30
- 231100000135 cytotoxicity Toxicity 0.000 description 30
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 29
- 239000000203 mixture Substances 0.000 description 29
- 238000003556 assay Methods 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- 230000004913 activation Effects 0.000 description 27
- 238000000684 flow cytometry Methods 0.000 description 26
- 241000282414 Homo sapiens Species 0.000 description 25
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 24
- 239000012636 effector Substances 0.000 description 21
- 210000000581 natural killer T-cell Anatomy 0.000 description 21
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 20
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 20
- 230000035755 proliferation Effects 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- 230000009089 cytolysis Effects 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 16
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 16
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 229940127130 immunocytokine Drugs 0.000 description 16
- 230000006698 induction Effects 0.000 description 16
- 125000000539 amino acid group Chemical group 0.000 description 15
- 230000005931 immune cell recruitment Effects 0.000 description 15
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 14
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 14
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 14
- 229910052693 Europium Inorganic materials 0.000 description 13
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 13
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 12
- 230000022534 cell killing Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000003285 pharmacodynamic effect Effects 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 10
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 10
- 229950002916 avelumab Drugs 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 150000004676 glycans Chemical class 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 235000013930 proline Nutrition 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 9
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 9
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 230000033581 fucosylation Effects 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 239000004471 Glycine Chemical group 0.000 description 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 229960005395 cetuximab Drugs 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- -1 ICOS Proteins 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 229930182830 galactose Natural products 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000003827 upregulation Effects 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 6
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 6
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 108010008707 Mucin-1 Proteins 0.000 description 6
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 6
- 230000006044 T cell activation Effects 0.000 description 6
- 230000006052 T cell proliferation Effects 0.000 description 6
- 229920004890 Triton X-100 Polymers 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 239000012911 assay medium Substances 0.000 description 6
- 230000035605 chemotaxis Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000030279 gene silencing Effects 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000025113 myeloid leukemia Diseases 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 108010073807 IgG Receptors Proteins 0.000 description 5
- 102000009490 IgG Receptors Human genes 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 5
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229940082789 erbitux Drugs 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 235000004400 serine Nutrition 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 206010057248 Cell death Diseases 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 4
- 239000002773 nucleotide Chemical group 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 125000005630 sialyl group Chemical group 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 3
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000003016 alphascreen Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000012642 immune effector Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 125000000741 isoleucyl group Chemical class [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010001498 Galectin 1 Proteins 0.000 description 2
- 102000000802 Galectin 3 Human genes 0.000 description 2
- 108010001517 Galectin 3 Proteins 0.000 description 2
- 102100021736 Galectin-1 Human genes 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000011198 co-culture assay Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 2
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000001483 mobilizing effect Effects 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 229940123189 CD40 agonist Drugs 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101100346929 Homo sapiens MUC1 gene Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 101100066433 Mus musculus Fcgr3 gene Proteins 0.000 description 1
- 206010028811 Natural killer-cell leukaemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 150000008444 O-glycosides Chemical group 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100269369 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AGE1 gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 230000006043 T cell recruitment Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical group C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 102000057266 human FCGR3A Human genes 0.000 description 1
- 102000057860 human MUC1 Human genes 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 201000010453 lymph node cancer Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000004990 primary immune cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 102220311640 rs1382779104 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 201000002743 tongue squamous cell carcinoma Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(i)MUC1に特異的に結合する抗体モジュールと、
(ii)IL−15モジュールと
を含む融合タンパク質構築物に関する。
定義
本発明は、IL−15またはそのバリアントとMUC1を標的とする抗がん抗体とが融合した融合タンパク質構築物の開発に基づく。確立された抗MUC1抗体は、腫瘍関連MUC1に結合し、細胞傷害免疫細胞を動員し活性化することによってその抗がん活性を発揮する。免疫細胞、特にナチュラルキラー細胞(NK細胞)の結合および活性化は、抗体Fc部分と免疫細胞上のFcγ受容体、特にFcγRIIIaの相互作用によって実現される。活性化されると、抗体依存性細胞傷害(antibody−dependent cellular cytotoxicity)(ADCC)が開始される。これを考慮して、本発明者らは、確立された抗MUC1抗体の有効性を、IL−15またはIL−15とIL−15受容体α鎖のsushiドメインの組合せをこれらの抗体に結合させることによってさらに改善した。IL−15は、NK細胞、NKT細胞およびT細胞の発生、活性化および増殖を誘導するサイトカインである。
(i)MUC1に特異的に結合する抗体モジュールと、
(ii)IL−15モジュールと
を含む融合タンパク質構築物を提供する。
抗MUC1抗体モジュール
IL−15モジュール
融合タンパク質構築物
融合タンパク質構築物のグリコシル化
Asn−GlcNAc−GlcNAc−Man−(Man−GlcNAc)2
(式中、Asnは抗体モジュールのポリペプチド部分のアスパラギン残基であり、GlcNAcはN−アセチルグルコサミンであり、Manはマンノースである)。末端GlcNAc残基はさらにガラクトース残基を有し得、これは必要に応じてシアル酸残基を有し得る。さらなるGlcNAc残基(バイセクト型GlcNAcと称される)をポリペプチドに最も近いManに結合させることができる。Asnに結合したGlcNAcにフコースを結合させることができる。
核酸、発現カセット、ベクター、細胞株および組成物
医療における使用
(i)細胞療法、例えば、CAR−T、TCR、NK、またはCDに基づく細胞療法;
(ii)免疫活性化抗体、例えば、二重特異性TまたはNK細胞エンゲージャーまたは他の免疫サイトカイン;
(iii)チェックポイント抗体、例えば、アンタゴニストまたはアゴニストチェックポイント抗体、例えば、CD3に対する抗体、PD−1に対する抗体、PD−L1に対する抗体、CD40に対する抗体、CD7に対する抗体、CD28に対する抗体、GITRに対する抗体、ICOSに対する抗体、OX40に対する抗体、4−1BBに対する抗体、CTLA−4に対する抗体、CD160に対する抗体、ガレクチン−3に対する抗体、およびガレクチン−1に対する抗体;
(iv)ワクチン接種治療;
(v)化学療法;
(vi)これだけに限定されないが、EGFRに対する抗体、HER2に対する抗体、TFαに対する抗体、LeYに対する抗体、CEAに対する抗体およびEpCAMに対する抗体などのADCC媒介性モノクローナル抗体を含めた、腫瘍を標的とする抗体;
(vii)がん細胞の表面上のTA−MUC1を、例えばEGFRを阻害することによって上方制御する治療。
特定の実施形態
(i)MUC1に特異的に結合する抗体モジュール(抗MUC1抗体モジュール)と、
(ii)IL−15モジュールと
を含む融合タンパク質構築物。
(i)抗MUC1抗体モジュールであって、2つの抗体重鎖および2つの抗体軽鎖を含み、各重鎖がVHドメイン、CH1ドメイン、ヒンジ領域、CH2ドメインおよびCH3ドメインを含み、各軽鎖がVLドメインおよびCLドメインを含む、抗体モジュールと、
(ii)それぞれがヒトIL−15を含む2つのIL−15モジュールと
を含む融合タンパク質構築物。
MUC1およびIL−15に特異的に結合する融合タンパク質構築物の産生。
MUC1特異的結合部分およびIL−15機能部分からなる融合タンパク質構築物を創製した。MUC1結合部分は、典型的な抗体Y形状を有するヒト化全長IgG1抗体分子PankoMab(ガチポツズマブ)である。抗MUC1抗体は、CH2ドメイン内に天然のグリコシル化部位(PM)を含むか、または、重鎖内に、グリコシル化を消滅させるN297A変異を有する(PM NA)。CH2ドメイン内にグリコシル化がないと、抗体は、Fcγ受容体に結合せず、ADCCを誘導することができない(Fcサイレンシングバリアント)。IL−15機能は、野生型配列(IL−15wt)または受容体結合を低下させる変異I67E(IL−15mut)を有する全長ヒトIL−15を融合することによって実現される。1つの構築物では、IL−15wtにはIL−15受容体α鎖のsushiドメインが付随する(IL−15sushi)。構築物の一般構造を図1に示す。
異なるPankoMabおよびIL−15バリアントの分析
(実施例2)
抗原結合
(実施例3)
IL−15受容体結合
(実施例4)
FcγRIIIa結合
(実施例5)
天然の細胞傷害の誘導
%特異的溶解=(実験放出−自然放出)/(最大放出−基礎放出)×100。
(実施例6)
ADCCアッセイ1
%特異的溶解=(実験放出−自然放出)/(最大放出−基礎放出)×100。
%自然溶解=(自然放出−基礎放出)/(最大放出−基礎放出)×100。
(実施例7)
ADCCアッセイ2
(実施例8)
3Dスフェロイドモデルにおける免疫細胞の動員
(実施例9)
免疫細胞活性化および増殖
(実施例10)
サイトカイン放出
(実施例11)
免疫抑制細胞の活性化
(実施例12)
走化性
(実施例13)
in vivoにおける薬物動態
(実施例14)
in vivoにおける薬力学
種々のPM−IL−15構築物設計の分析
(実施例15)
抗原結合
(実施例16)
IL−15受容体結合
(実施例17)
細胞増殖の誘導
(実施例18)
免疫細胞活性化の誘導
(実施例19)
抗腫瘍細胞傷害の誘導
(実施例20)
in vivoにおける薬物動態に対する構築物設計の影響
(実施例21)
in vivoにおける薬力学に対する構築物設計の影響
(実施例22)
in vivo腫瘍モデルにおける治療有効性
PM−IL−15と他の治療薬との組合せ
(実施例23)
PM−IL−15とPM−CD3の組合せを使用した免疫細胞の活性化
(実施例24)
PM−IL−15とPM−CD3の組合せを使用した免疫細胞の増殖
(実施例25)
PM−CD3と組合せたPM−IL−15の細胞傷害
(実施例26)
PM−IL−15免疫サイトカインとPD−L1またはPD−1標的化治療との組合せ
(実施例27)
PM−IL−15免疫サイトカインと抗EGFR治療薬との組合せ
(実施例28)
CD40アゴニストによるIL−15R発現の上方制御
寄託された生物材料の識別
Claims (19)
- (i)MUC1に特異的に結合する抗体モジュールと、
(ii)IL−15モジュールと
を含む融合タンパク質構築物。 - 前記抗体モジュールが、以下の特性
(a)重鎖可変ドメインおよび軽鎖可変ドメインを含む;
(c)2つの抗体重鎖および2つの抗体軽鎖を含む;
(d)IgG型抗体モジュール、特に、IgG1型抗体モジュールである;
(e)TA−MUC1エピトープに特異的に結合する;
(f)配列番号1のアミノ酸配列を有するCDR−H1、配列番号3のアミノ酸配列を有するCDR−H2、配列番号5のアミノ酸配列を有するCDR−H3、配列番号10のアミノ酸配列を有するCDR−L1、配列番号12のアミノ酸配列を有するCDR−L2および配列番号14のアミノ酸配列を有するCDR−L3を有する一群のCDR配列を含む;
(g)配列番号1のアミノ酸配列を有するCDR−H1、配列番号33のアミノ酸配列を有するCDR−H2、配列番号5のアミノ酸配列を有するCDR−H3、配列番号10のアミノ酸配列を有するCDR−L1、配列番号12のアミノ酸配列を有するCDR−L2および配列番号14のアミノ酸配列を有するCDR−L3を有する一群のCDR配列を含む;
(h)配列番号9もしくは34のアミノ酸配列またはそれと少なくとも80%同一であるアミノ酸配列を含む重鎖可変領域を少なくとも1つ、特に2つ、および配列番号18のアミノ酸配列またはそれと少なくとも80%同一であるアミノ酸配列を含む軽鎖可変領域を少なくとも1つ、特に2つ含む
の1つまたは複数を有する、請求項1に記載の融合タンパク質構築物。 - 前記IL−15モジュールが、ヒトIL−15またはその断片を含む、請求項1または2に記載の融合タンパク質構築物。
- 前記ヒトIL−15またはその断片が、以下の特性
(a)IL−2受容体β鎖、共通γ鎖およびIL−15受容体α鎖を含むインターロイキン受容体に特異的に結合する;
(b)配列番号21の配列を含む;
(c)I67Eなどの、受容体結合を低下させる変異を含む
の1つまたは複数を有する、請求項3に記載の融合タンパク質構築物。 - 前記IL−15モジュールが、ヒトIL−15に特異的に結合するヒトIL−15受容体α鎖またはその断片をさらに含む、請求項3または4に記載の融合タンパク質構築物。
- 前記IL−15モジュールが、IL−15に特異的に結合するIL−15受容体α鎖もその断片も含まない、請求項1から4までのいずれか一項に記載の融合タンパク質構築物。
- 前記抗体モジュールが、前記抗体重鎖内の任意のCH2ドメイン内にN−グリコシル化部位を含む、請求項1から6までのいずれか一項に記載の融合タンパク質構築物。
- (i)2つの抗体重鎖および2つの抗体軽鎖を含む1つの抗体モジュールと、
(ii)2つのIL−15モジュールであって、一方のIL−15モジュールが、各抗体重鎖のC末端にペプチドリンカーを介して融合している、2つのIL−15モジュールと
を含む、請求項1から7までのいずれか一項に記載の融合タンパク質構築物。 - (i)2つの抗体重鎖および2つの抗体軽鎖を含む1つの抗体モジュールと、
(ii)2つのIL−15モジュールであって、一方のIL−15モジュールが、各抗体軽鎖のC末端にペプチドリンカーを介して融合している、2つのIL−15モジュールと
を含む、請求項1から7までのいずれか一項に記載の融合タンパク質構築物。 - それとコンジュゲートしたさらなる作用物質を含む、請求項1から9までのいずれか一項に記載の融合タンパク質構築物。
- 請求項1から10までのいずれか一項に記載の融合タンパク質構築物をコードする核酸。
- 請求項11に記載の核酸および前記核酸と作用的に接続したプロモーターを含む発現カセットまたはベクター。
- 請求項11に記載の核酸または請求項12に記載の発現カセットもしくはベクターを含む宿主細胞。
- 請求項1から10までのいずれか一項に記載の融合タンパク質構築物、ならびに溶媒、希釈剤、および賦形剤からなる群から選択される1つまたは複数のさらなる構成成分を含む医薬組成物。
- 医療に使用するための、請求項1から10までのいずれか一項に記載の融合タンパク質構築物または請求項14に記載の医薬組成物。
- がんなどの、異常な細胞成長に関連する疾患、細菌感染症、ウイルス感染症、真菌感染症または寄生虫感染症などの感染症、および、免疫不全などの、免疫活性の低下に関連する疾患の処置、予後判定、診断および/またはモニタリングにおいて使用するための、請求項1から10までのいずれか一項に記載の融合タンパク質構築物または請求項14に記載の医薬組成物。
- 前記がんが、乳がん、結腸がん、胃がん、肝がん、膵がん、腎がん、血液がん、肺がん、子宮内膜がん、甲状腺がんおよび卵巣がんからなる群から選択される、請求項16に記載の、がんの処置、予後判定、診断および/またはモニタリングにおいて使用するための融合タンパク質構築物または医薬組成物。
- 前記融合タンパク質構築物が、さらなる作用物質と組み合わせて使用される、請求項15から17までのいずれか一項に記載の、医療に使用するための融合タンパク質構築物または医薬組成物。
- 前記さらなる作用物質が、MUC1およびCD3を標的とする二重特異性抗体、PD−L1に対する抗体、EGFRに対する抗体、ならびにCD40に対する抗体からなる群から選択される、請求項18に記載の、医療に使用するための融合タンパク質構築物または医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023156280A JP2023164704A (ja) | 2018-03-01 | 2023-09-21 | 抗muc1抗体およびil-15を含む融合タンパク質構築物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18159449.0 | 2018-03-01 | ||
EP18159449 | 2018-03-01 | ||
EP18194290 | 2018-09-13 | ||
EP18194290.5 | 2018-09-13 | ||
PCT/EP2019/055125 WO2019166617A1 (en) | 2018-03-01 | 2019-03-01 | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023156280A Division JP2023164704A (ja) | 2018-03-01 | 2023-09-21 | 抗muc1抗体およびil-15を含む融合タンパク質構築物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021514625A true JP2021514625A (ja) | 2021-06-17 |
Family
ID=65628788
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020544404A Pending JP2021514625A (ja) | 2018-03-01 | 2019-03-01 | 抗muc1抗体およびil−15を含む融合タンパク質構築物 |
JP2023156280A Pending JP2023164704A (ja) | 2018-03-01 | 2023-09-21 | 抗muc1抗体およびil-15を含む融合タンパク質構築物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023156280A Pending JP2023164704A (ja) | 2018-03-01 | 2023-09-21 | 抗muc1抗体およびil-15を含む融合タンパク質構築物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210107961A1 (ja) |
EP (1) | EP3759144A1 (ja) |
JP (2) | JP2021514625A (ja) |
KR (1) | KR20200128026A (ja) |
CN (1) | CN111819203A (ja) |
AU (1) | AU2019226387A1 (ja) |
BR (1) | BR112020015202A2 (ja) |
CA (1) | CA3090407A1 (ja) |
IL (1) | IL276760A (ja) |
WO (1) | WO2019166617A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117815404A (zh) | 2018-05-18 | 2024-04-05 | 第一三共株式会社 | 抗-muc1抗体-药物缀合物 |
EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
US20210244821A1 (en) * | 2020-02-05 | 2021-08-12 | Novartis Ag | Cho cell expressed het il-15 |
BR112023027312A2 (pt) * | 2021-06-23 | 2024-03-12 | Cytune Pharma | Imunocitocina |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003535908A (ja) * | 2000-06-22 | 2003-12-02 | アイデック ファーマスーティカルズ コーポレイション | 二重特異性融合タンパク及び標的細胞を殺傷するエフェクター細胞を増強するための使用方法 |
JP2013500703A (ja) * | 2009-07-31 | 2013-01-10 | グリコトープ ゲーエムベーハー | Muc1抗体 |
JP2017521410A (ja) * | 2014-06-30 | 2017-08-03 | アルター・バイオサイエンス・コーポレーション | Il−15ベース分子及びその使用方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
BRPI0716997B8 (pt) | 2006-09-10 | 2021-05-25 | Glycotope Gmbh | proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma |
PT2160401E (pt) * | 2007-05-11 | 2014-10-30 | Altor Bioscience Corp | Moléculas de fusão e variantes de il-15 |
US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
KR102463844B1 (ko) * | 2016-05-27 | 2022-11-08 | 알토 바이오사이언스 코포레이션 | Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명 |
AU2018241781A1 (en) | 2017-03-29 | 2019-07-18 | Glycotope Gmbh | Multispecific antibody constructs binding to MUC1 and CD3 |
JP2020511959A (ja) | 2017-03-29 | 2020-04-23 | グリコトープ ゲーエムベーハー | ヒト化抗cd40抗体 |
EP3601349A1 (en) | 2017-03-29 | 2020-02-05 | Glycotope GmbH | Pd-l1 and ta-muc1 antibodies |
-
2019
- 2019-03-01 US US16/971,756 patent/US20210107961A1/en active Pending
- 2019-03-01 EP EP19708308.2A patent/EP3759144A1/en active Pending
- 2019-03-01 BR BR112020015202-1A patent/BR112020015202A2/pt unknown
- 2019-03-01 CN CN201980014487.XA patent/CN111819203A/zh active Pending
- 2019-03-01 AU AU2019226387A patent/AU2019226387A1/en active Pending
- 2019-03-01 CA CA3090407A patent/CA3090407A1/en active Pending
- 2019-03-01 KR KR1020207025639A patent/KR20200128026A/ko unknown
- 2019-03-01 WO PCT/EP2019/055125 patent/WO2019166617A1/en active Application Filing
- 2019-03-01 JP JP2020544404A patent/JP2021514625A/ja active Pending
-
2020
- 2020-08-17 IL IL276760A patent/IL276760A/en unknown
-
2023
- 2023-09-21 JP JP2023156280A patent/JP2023164704A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003535908A (ja) * | 2000-06-22 | 2003-12-02 | アイデック ファーマスーティカルズ コーポレイション | 二重特異性融合タンパク及び標的細胞を殺傷するエフェクター細胞を増強するための使用方法 |
JP2013500703A (ja) * | 2009-07-31 | 2013-01-10 | グリコトープ ゲーエムベーハー | Muc1抗体 |
JP2017521410A (ja) * | 2014-06-30 | 2017-08-03 | アルター・バイオサイエンス・コーポレーション | Il−15ベース分子及びその使用方法 |
Non-Patent Citations (2)
Title |
---|
JOURNAL OF IMMUNOLOGICAL SCIENCES, vol. 2, JPN6022054309, January 2018 (2018-01-01), pages 15 - 18, ISSN: 0005067100 * |
MOLECULAR CANCER THERAPEUTICS, vol. 11, JPN6023020440, 2012, pages 1279 - 1288, ISSN: 0005067101 * |
Also Published As
Publication number | Publication date |
---|---|
CA3090407A1 (en) | 2019-09-06 |
AU2019226387A1 (en) | 2020-08-20 |
WO2019166617A1 (en) | 2019-09-06 |
BR112020015202A2 (pt) | 2020-12-29 |
CN111819203A (zh) | 2020-10-23 |
IL276760A (en) | 2020-10-29 |
KR20200128026A (ko) | 2020-11-11 |
JP2023164704A (ja) | 2023-11-10 |
US20210107961A1 (en) | 2021-04-15 |
EP3759144A1 (en) | 2021-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6799101B2 (ja) | クローディンを発現するガン疾患を処置するための剤 | |
CN107835820B (zh) | 识别癌症特异性IL13Rα2的CAR T细胞 | |
JP7280827B2 (ja) | Axlまたはror2に対するキメラ抗原受容体およびその使用方法 | |
CN107683289B (zh) | IL13Rα2结合剂和其在癌症治疗中的用途 | |
JP2019525771A (ja) | プログラム死1リガンド1(pd−l1)結合タンパク質及びその使用方法 | |
JP2022516557A (ja) | 修飾il-2ポリペプチドを含むポリペプチド及びその使用 | |
JP2021514625A (ja) | 抗muc1抗体およびil−15を含む融合タンパク質構築物 | |
US11529425B2 (en) | Immunoconjugates comprising signal regulatory protein alpha | |
JP7462611B2 (ja) | Ox40結合性ポリペプチド及びその使用 | |
JP2020515532A (ja) | Muc1およびcd3に結合する多重特異的抗体構築物 | |
WO2020244526A1 (zh) | 一种抗ceacam5的单克隆抗体及其制备方法和用途 | |
CN114040927A (zh) | 结合cd33的多肽及其用途 | |
JP2023547380A (ja) | 新規の抗lilrb2抗体および誘導体生成物 | |
KR20240046224A (ko) | 이중특이성 항체 및 그 용도 | |
TW202304997A (zh) | 新型抗cd4抗體 | |
CN115403671A (zh) | 靶向Claudin18.2的纳米抗体及其用途 | |
JP2020530766A (ja) | フィブロネクチンiii型ドメインに対する抗原結合領域及びその使用方法 | |
CN114616247B (zh) | Ox40/pd-l1双特异性抗体 | |
TW202302626A (zh) | 用於調節tgf-b信息傳導之細胞療法組成物及方法 | |
TWI844684B (zh) | 一種抗ceacam5的單殖株抗體及其製備方法和用途 | |
WO2024094159A1 (zh) | 靶向人源ror1的单域抗体 | |
WO2023133393A1 (en) | Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof | |
WO2023133394A1 (en) | Gamma delta t-cell-binding polypeptides and uses thereof | |
CN117377687A (zh) | 抗癌组合疗法中的ltbr激动剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201009 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230317 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230921 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230928 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20231102 |